Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study
- Publication date
- 1 January 2021
- Publisher
- Европейского общества медицинской онкологииEuropean Society for Medical Oncology and the official journal of the Японского общества медицинской онкологии.Japanese Society of Medical Oncology